Several analysts have recently updated their ratings and price targets for Perspective Therapeutics (NYSEAMERICAN: CATX):
- 11/10/2026 – Perspective Therapeutics had its “outperform” rating reaffirmed by Wedbush.
- 10/30/2026 – Perspective Therapeutics had its “outperform” rating reaffirmed by BMO Capital Markets.
- 10/26/2026 – Perspective Therapeutics had its “buy” rating reaffirmed by BTIG Research.
- 10/26/2026 – Perspective Therapeutics was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $4.00 price target on the stock, down from $14.00.
- 10/7/2026 – Perspective Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $14.00 price target on the stock.
- 9/18/2026 – Perspective Therapeutics is now covered by William Blair. They set an “outperform” rating on the stock.
- 9/15/2026 – Perspective Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
Perspective Therapeutics Stock Up 1.9%
Shares of CATX stock opened at $0.86 on Tuesday. The stock has a fifty day moving average price of $2.29 and a 200 day moving average price of $3.48. Perspective Therapeutics, Inc. has a 1 year low of $0.78 and a 1 year high of $6.16.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. As a group, equities analysts forecast that Perspective Therapeutics, Inc. will post -0.98 earnings per share for the current year.
Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.
The company’s lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.
Read More
- Five stocks we like better than Perspective Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Perspective Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
